Skip to content

    Diabetes Health Center

    Font Size
    A
    A
    A

    FDA to Lift Restrictions on Diabetes Drug Avandia

    Not all experts are happy with granting wider access to the troubled medication, however

    WebMD News from HealthDay

    By Dennis Thompson

    HealthDay Reporter

    MONDAY, Nov. 25, 2013 (HealthDay News) -- The U.S. Food and Drug Administration announced Monday that it is lifting the tough safety restrictions it imposed on the diabetes drug Avandia two years ago because of reported links to heart problems.

    The agency's decision was expected, and follows up on a June vote by an expert advisory panel to rescind the restrictions, based on new data that suggested the medication may not be as harmful as once thought.

    Avandia had been taken off drug store shelves in 2011, and its use restricted to patients who first signed a waiver saying they understood the possible risks. Only specially registered pharmacies could dispense Avandia.

    But an independent review by Duke University researchers, based on Avandia's original clinical trial, concluded that patients had no elevated risk of heart attack or death compared with those taking standard diabetes drugs.

    "Our actions today reflect the most current scientific knowledge about the risks and benefits of this drug," Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, said in a statement. "Given these new results, our level of concern is considerably reduced. Thus, we are requiring the removal of certain prescribing restrictions."

    Dr. Steven Nissen, head of cardiology at Cleveland Clinic, first sounded the alarm about Avandia in 2007 with an analysis of 42 studies that showed that the medication caused a 43 percent increased risk of heart attack.

    Following his study, an FDA analysis of more than 50 studies concluded that Avandia was linked to an increased risk of heart problems, and the agency decided to pull the drug from pharmacy shelves.

    However, the FDA also asked drug maker GlaxoSmithKline to review key aspects of Avandia's clinical trial related to heart safety. This was the review that led to Monday's decision.

    Nissen condemned the FDA's latest action.

    "This decision is not in the public interest," Nissen said. "It's really more about the FDA than it is about the drug. It does not make any good regulatory sense, and in fact it's rather bizarre."

    Today on WebMD

    Diabetic tools
    Symptoms, diagnosis, treatment, and more.
    woman flexing muscles
    10 strength training exercises.
     
    Blood sugar test
    12 practical tips.
    Tom Hanks
    Stars living with type 1 or type 2.
     
    kenneth fujioka, md
    Video
    Can Vinegar Treat Diabetes
    Article
     
    Middle aged person
    Tool
    jennie brand miller
    Video
     

    Prediabetes How to Prevent Type 2 Diabetes
    Article
    type 2 diabetes
    Slideshow
     
    food fitness planner
    Tool
    feet
    Slideshow